Erratum to: Add-On Adefovir Is Superior to a Switch to Entecavir as Rescue Therapy for Lamivudine-Resistant Chronic Hepatitis B

Dig Dis Sci Erratum to: Add-On Adefovir Is Superior to a Switch to Entecavir as Rescue Therapy for Lamivudine-Resistant Chronic Hepatitis B Goh Eun Chung 0 1 2 Won Kim 0 1 2 Kook Lae Lee 0 1 2 Sang Youn Hwang 0 1 2 Jeong-Hoon Lee 0 1 2 Hwi Young Kim 0 1 2 Yong Jin Jung 0 1 2 Donghee Kim 0 1 2 Ji Bong Jeong 0 1 2 Byeong Gwan Kim 0 1 2 Yoon Jun Kim 0 1 2 Jung-Hwan Yoon 0 1 2 Hyo-Suk Lee 0 1 2 0 S. Y. Hwang J.-H. Lee H. Y. Kim Y. J. Kim J.-H. Yoon H.-S. Lee Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine , Seoul , Republic of Korea 1 W. Kim (&) K. L. Lee Y. J. Jung J. B. Jeong B. G. Kim Department of Internal Medicine, Seoul Metropolitan Government Seoul National University, Boramae Medical Center 39 , Boramae Road, Dongjakgu, Seoul 156-707 , Republic of Korea 2 G. E. Chung D. Kim Department of Internal Medicine, Gangnam Healthcare Center, Seoul National University Hospital , Seoul , Republic of Korea Biochemical and Serological Response were found between the two groups in the mean reduction and normalization of ALT at week 48. Among HBeAgpositive patients, HBeAg seroconversion (66.7% in the ETV group vs. 38.4% in the add-on ADV group) and the mean time to HBeAg seroconversion (11.83 8.95 months in the ETV group vs. 5.40 1.45 months in the add-on ADV group) were similar in the two groups (P = 0.229 and P = 0.190). - While describing Biochemical and Serological Response, values for ETV group (68.8%) and add-on ADV group (31.3%) are erroneously published. The correct values are ETV group should be 66.7% and add-on ADV group should be 38.4%. Corrected text is given below. Serum ALT levels decreased during the treatment period in both groups (Table 2). However, no significant differences (...truncated)